$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Clinical effects and patient evaluations of sparsentan (sparsentan) in the treatment of kidney disease
2026-02-01 22:25:32
Check Details
How many years can long-term maintenance treatment with Ixazomib (Enleri) be maintained and its efficacy evaluated?
2026-02-01 22:25:32
Check Details
Lurbinectedin/Lurbinectedin’s domestic launch time and approval information
2026-02-01 22:25:32
Check Details
Detailed explanation of the usage of F/TAF PrEP and analysis of correct taking methods and precautions
2026-02-01 22:25:32
Check Details
Analysis of the key contents and medication guidance of the official instructions for Febuxostat (Febuxostat)
2026-02-01 22:25:32
Check Details
How much does a box of furmonertinib cost and analysis of price differences in different regions
2026-02-01 22:25:32
Check Details
Detailed description of the main functions, efficacy and applicable symptoms of ensifentrine-Ohtuvayre
2026-02-01 22:25:32
Check Details
Interpretation of the usage, dosage and adverse reaction instructions of Roaccutane (isotretinoin) soft capsules
2026-02-01 22:25:32
Check Details
Comprehensive interpretation of the key contents and precautions for use of Doxorubicin drug instructions
2026-02-01 22:25:32
Check Details
When will Everolimus be launched in the country and the latest market trends
2026-02-01 22:25:32
Check Details
Is estramustine (Adelax) a chemotherapy drug and an introduction to its pharmacological properties
2026-02-01 22:25:32
Check Details
Recommended usage and dosage of seripalase (BRINEURA) and key matters to note when taking it
2026-02-01 22:25:32
Check Details
1
2
...
2155
2156
2157
2158
2159
2160
2161
...
10240
10241
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Momelotinib for Myelofibrosis: Spleen Response, Symptom Improvement and Efficacy Monitoring
2
Pirtobrutinib and Risks of Atrial Fibrillation and Bleeding: Mechanism, Data Interpretation and Monitoring
3
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
4
Ixazomib (Ninlaro) Dosing Schedule, Missed Dose Management and Cycle Planning in 28‑Day Regimen
5
Ponatinib in the PACE Phase II Trial: Response Data in Resistant CML and Ph+ ALL
6
Selumetinib for NF1-Related Plexiform Neurofibromas: Time to Response and Response Assessment
7
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
8
Ganaxolone Common Side Effects: Somnolence, Sedation and Safety Notes
9
Baxdrostat: Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor
10
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
11
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
12
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks